In brief, we present a case of acute myeloid leukemia (AML) with 5, 17 and 18 monosomies as stemline clonal abnormality in his cytogenetic analysis. To the best of our knowledge, this is the first report of such a chromosomal abnormality as a clonal aberration in AML with M0 French-American-British (FAB) type. It seems that this monosomal karyotype imposed adverse prognosis on this patient and could be related to the rapid and malignant course of the disease as seen.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients.
J Hematol Oncol
August 2024
Department of Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Article Synopsis
- Acute myeloid leukemia (AML) often involves deletions of chromosome 7, which are linked to poor patient outcomes, but the full impact of other genetic changes related to this is not well understood.
- Researchers analyzed genetic alterations in 519 AML patients, using whole-exome sequencing and a specialized gene panel, finding that mutations in TP53, which occurred in 33% of cases, were among the most common.
- The study identified specific genes, like TP53 and PTPN11, that have a significant negative effect on overall and relapse-free survival, highlighting the complex relationship between chromosome 7 abnormalities and patient prognosis in AML.
Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial.
Lancet Haematol
September 2024
Département (DMU) d'hématologie et immunologie, Service d'hématologie Seniors, Hôpital St Louis, Université de Paris, APHP Nord Paris, France.
Background: Lenalidomide is the standard of care for patients who are transfusion dependent with chromosome 5q deletion (del[5q]) myelodysplastic syndromes. In the SintraREV trial, we aimed to investigate whether an early intervention of low lenalidomide doses for 2 years could delay transfusion dependency in patients with anaemia who were not transfusion dependent.
Methods: This randomised, double-blind, phase 3 trial, was conducted at 22 sites (University Hospitals) in Spain, France, and Germany.
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy.
Nat Commun
October 2021
Department of Genomic Medicine, University of Texas M D Anderson Cancer Center, Houston, TX, USA.
In contrast to the curative effect of allogenic stem cell transplantation in acute myeloid leukemia via T cell activity, only modest responses are achieved with checkpoint-blockade therapy, which might be explained by T cell phenotypes and T cell receptor (TCR) repertoires. Here, we show by paired single-cell RNA analysis and TCR repertoire profiling of bone marrow cells in relapsed/refractory acute myeloid leukemia patients pre/post azacytidine+nivolumab treatment that the disease-related T cell subsets are highly heterogeneous, and their abundance changes following PD-1 blockade-based treatment. TCR repertoires expand and primarily emerge from CD8 cells in patients responding to treatment or having a stable disease, while TCR repertoires contract in therapyresistant patients.
View Article and Find Full Text PDFA Clone with 5, 17 and 18 Monosomies as Stemline in a Patient with De novo Acute Myeloid Leukemia.
Arch Iran Med
May 2016
Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
In brief, we present a case of acute myeloid leukemia (AML) with 5, 17 and 18 monosomies as stemline clonal abnormality in his cytogenetic analysis. To the best of our knowledge, this is the first report of such a chromosomal abnormality as a clonal aberration in AML with M0 French-American-British (FAB) type. It seems that this monosomal karyotype imposed adverse prognosis on this patient and could be related to the rapid and malignant course of the disease as seen.
View Article and Find Full Text PDFDel(20q) in patients with chronic lymphocytic leukemia: a therapy-related abnormality involving lymphoid or myeloid cells.
Mod Pathol
August 2015
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Deletion 20q (Del(20q)), a common cytogenetic abnormality in myeloid neoplasms, is rare in chronic lymphocytic leukemia. We report 64 patients with chronic lymphocytic leukemia and del(20q), as the sole abnormality in 40, a stemline abnormality in 21, and a secondary abnormality in 3 cases. Fluorescence in situ hybridization (FISH) analysis revealed an additional high-risk abnormality, del(11q) or del(17p), in 25/64 (39%) cases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!